Down syndrome, increased risk of dementia and lipid disturbances

1Weijerman ME, van Furth AM, Vonk Noordegraaf A, van Wouwe JP, Broers CJM, Gemke RJBJ. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. J Pediatr. Jan 2008;vol. 152, no. 1:15-19.Weijerman ME van Furth AM Vonk Noordegraaf A van Wouwe JP Broers CJM Gemke RJBJ. Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study J Pediatr. Jan 2008vol. 152 no. 115 1910.1016/j.jpeds.2007.09.045Search in Google Scholar

2Shin M, Besser LM, Kucik JE, Lu C, Siffel C, Correa A. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. Pediatrics Dec 2009;vol. 124, no. 6:1565-1571.Shin M Besser LM Kucik JE Lu C Si" el C Correa A. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States Pediatrics Dec 2009vol. 124 no. 61565 157110.1542/peds.2009-0745Search in Google Scholar

3Wilcock DM, Griffin WST. Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J. Neuroinflammation 2013;vol. 10:84.Wilcock DM Griffin WST Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis J. Neuroinflammation 2013vol. 108410.1186/1742-2094-10-84Search in Google Scholar

4Weijerman ME, Broers CJM, van der Plas RN. New insights into the support of children with Down syndrome. Ned. Tijdschr. Geneeskd. 2013;vol. 157, no. 6:A5330.Weijerman ME Broers CJM van der Plas RN. New insights into the support of children with Down syndrome Ned. Tijdschr. Geneeskd 2013vol. 157 no. 6A5330Search in Google Scholar

5Hijii T, Fukushige J, Igarashi H, Takahashi N, Ueda K.Life expectancy and social adaptation in individuals with Down syndrome with and without surgery for congenital heart disease. Clin Pediatr. (Phila). Jun 1997; vol. 36, no. 6:327-332.Hijii T Fukushige J Igarashi H Takahashi N Ueda K Life expectancy and social adaptation in individuals with Down syndrome with and without surgery for congenital heart disease. Clin Pediatr (Phila). Jun 1997 vol. 36 no. 6327 33210.1177/000992289703600603Search in Google Scholar

6Bittles AH, Glasson EJ. Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol. Apr 2004;vol. 46, no. 4:282-286.Bittles AH Glasson EJ Clinical, social, and ethical implications of changing life expectancy in Down syndrome Dev Med Child Neurol. Apr 2004vol. 46 no. 4282 28610.1111/j.1469-8749.2004.tb00483.xSearch in Google Scholar

7Yla-Herttuala S, Luoma J, Nikkari T, Kivimaki T. Down’s syndrome and atherosclerosis. Atherosclerosis Apr 1989;vol. 76, no. 2-3:269-272.Yla-Herttuala S Luoma J Nikkari T Kivimaki T Down’s syndrome and atherosclerosis Atherosclerosis Apr 1989vol. 76 no. 2-3269 27210.1016/0021-9150(89)90110-XSearch in Google Scholar

8Chaney RH. Neurogenic atherosclerosis in mentally retarded persons. J Ment Defic Res. Sep 1987;vol. 31 (Pt 3):235-240.Chaney RH Neurogenic atherosclerosis in mentally retarded persons J Ment Defic Res. Sep 1987vol. 31 Pt 3235 24010.1111/j.1365-2788.1987.tb01366.x2960814Search in Google Scholar

9Pueschel SM, Craig WY, Haddow JE. Lipids and lipoproteins in persons with Down’s syndrome. J Intellect Disabil Res. Aug 1992;vol. 36 (Pt 4):365-369.Pueschel SM Craig WY Haddow JE Lipids and lipoproteins in persons with Down’s syndrome J Intellect Disabil Res. Aug 1992vol. 36 Pt 4365 36910.1111/j.1365-2788.1992.tb00535.x1388078Search in Google Scholar

10Lott IT, Head E. Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging Mar 2005;vol. 26, no. 3:383-389.Lott IT Head E Alzheimer disease and Down syndrome: factors in pathogenesis Neurobiol Aging Mar 2005vol. 26 no. 3383 38910.1016/j.neurobiolaging.2004.08.00515639317Search in Google Scholar

11Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ, Nolan D, Gandy SE, Martins RN. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Mol Psychiatry Aug 2006;vol. 11, no. 8:721-736.Martins IJ Hone E Foster JK Sunram-Lea SI Gnjec A Fuller SJ Nolan D Gandy SE Martins RN Apolipoprotein E cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease Mol Psychiatry Aug 2006vol. 11 no. 8721 73610.1038/sj.mp.400185416786033Search in Google Scholar

12Wierzba J. Zespół Downa i medycyna : praca zbiorowa. Warszawa : Stowarzyszenie Rodzin i Opiekunów Osób z Zespołem Downa Bardziej Kochani, 2014.Wierzba J Zespół Downa i medycyna : praca zbiorowa Warszawa : Stowarzyszenie Rodzin i Opiekunów Osób z Zespołem Downa Bardziej Kochani 2014Search in Google Scholar

13Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis. Feb 1996;vol. 3, no. 1:16-32.Lemere CA Blusztajn JK Yamaguchi H Wisniewski T Saido TC Selkoe DJ Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation Neurobiol Dis. Feb 1996vol. 3 no. 116 3210.1006/nbdi.1996.00039173910Search in Google Scholar

14Hof PR, Bouras C, Perl DP, Sparks, DL Mehta N, Morrison JH. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down’s syndrome. Quantitative regional analysis and comparison with Alzheimer’s disease. Arch Neurol. Apr 1995;vol. 52, no. 4:379-391.Hof PR Bouras C Perl DP Sparks DL Mehta N Morrison JH. Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down’s syndrome Quantitative regional analysis and comparison with Alzheimer’s disease. Arch Neurol. Apr 1995vol. 52 no. 4379 39110.1001/archneur.1995.005402800650207710374Search in Google Scholar

15Rocca WA, Amaducci LA, Schoenberg BS Epidemiology of clinically diagnosed Alzheimer’s disease. Ann Neurol. May 1986;vol. 19, no. 5:415-424.Rocca WA Amaducci LA Schoenberg BS Epidemiology of clinically diagnosed Alzheimer’s disease. Ann Neurol May 1986vol. 19 no. 5415 42410.1002/ana.4101905023717905Search in Google Scholar

16Mayeux R, Honig LS, Tang M-X, Manly J, Stern Y, Schupf N, Mehta PD. Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology Nov 2003; vol. 61, no. 9:1185-1190.Mayeux R Honig LS Tang M-X Manly J Stern Y Schupf N Mehta PD Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk Neurology Nov 2003 vol. 61 no. 91185 119010.1212/01.WNL.0000091890.32140.8F14610118Search in Google Scholar

17Bates KA, Sohrabi HR, Rodrigues M, Beilby J, Dhaliwal SS, Taddei K, Criddle A et al. Association of cardiovascular factors and Alzheimer’s disease plasma amyloid-beta protein in subjective memory complainers. J Alzheimer Dis. 2009;vol. 17, no. 2:305-318.Bates KA Sohrabi HR Rodrigues M Beilby J Dhaliwal SS Taddei K Criddle A et al Association of cardiovascular factors and Alzheimer’s disease plasma amyloid-beta protein in subjective memory complainers J Alzheimer Dis 2009vol. 17 no. 2305 31810.3233/JAD-2009-105019363264Search in Google Scholar

18Ward MA, Carlsson CM, Trivedi MA, Sager MA, Johnson SC. The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study. BMC Neurol. Dec 2005; vol. 5:23.Ward MA Carlsson CM Trivedi MA Sager MA Johnson SC The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study BMC Neurol. Dec 2005 vol. 52310.1186/1471-2377-5-23132525416321166Search in Google Scholar

19Kramer AF, Erickson KI, Colcombe SJ. Exercise, cognition, and the aging brain. J Appl Physiol. Oct 2006;vol. 101, no. 4-1237-1242.Kramer AF Erickson KI Colcombe SJ Exercise, cognition, and the aging brain J Appl Physiol. Oct 2006vol. 101 no. 4-1237-124210.1152/japplphysiol.00500.200616778001Search in Google Scholar

20Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB. A genotype of exceptional longevity is associated with preservation of cognitive function. Neurology Dec 2006;vol. 67, no. 12:2170-2175.Barzilai N Atzmon G Derby CA Bauman JM Lipton RB A genotype of exceptional longevity is associated with preservation of cognitive function Neurology Dec 2006vol. 67 no. 122170 217510.1212/01.wnl.0000249116.50854.6517190939Search in Google Scholar

21McGrowder D, Riley C, Morrison EYSA, Gordon L. The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol 2011;vol. 2011;496925.McGrowder D Riley C Morrison EYSA Gordon L The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer Cholesterol 2011vol. 201149692510.1155/2011/496925306589521490772Search in Google Scholar

22Kontush A, Chapman MJ. HDL: close to our memories? Arteriosclerosis, thrombosis, and vascular biology. Aug 2008;vol. 28, no. 8. United States:1418-1420.Kontush A Chapman MJ HDL: close to our memories? Arteriosclerosis, thrombosis, and vascular biology Aug 2008vol. 28 no. 8 United States:1418-142010.1161/ATVBAHA.108.16971418650505Search in Google Scholar

23Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S. et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. Feb 2008;vol. 118, no. 2:671-682.Wahrle SE Jiang H Parsadanian M Kim J Li A Knoten A Jain S. et al Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease J Clin Invest. Feb 2008vol. 118 no. 2671 68210.1172/JCI33622Search in Google Scholar

24Olesen OF, Dago L. High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils. Biochem Biophys Res Commun. Apr 2000;vol. 270, no. 1:62-66.Olesen OF Dago L High density lipoprotein inhibits assembly of amyloid beta-peptides into fibrils Biochem Biophys Res Commun. Apr 2000vol. 270 no. 162 6610.1006/bbrc.2000.2372Search in Google Scholar

25Hardy J, Cullen K. Amyloid at the blood vessel wall. Nature medicine, Jul 2006;vol. 12, no. 7. United States:756-757.Hardy J Cullen K Amyloid at the blood vessel wall Nature medicine, Jul 2006vol. 12 no. 7 United States:756-75710.1038/nm0706-756Search in Google Scholar

26Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arterioscler Thromb Vasc Biol. Aug 2008;vol. 28, no. 8:1556-1562.Singh-Manoux A Gimeno D Kivimaki M Brunner E Marmot MG. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study Arterioscler Thromb Vasc Biol. Aug 2008vol. 28 no. 81556 156210.1161/ATVBAHA.108.163998Search in Google Scholar

27Reitz C, Tang M-X, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol. May 2004;vol. 61, no. 5:705-714.Reitz C Tang M-X Luchsinger J Mayeux R Relation of plasma lipids to Alzheimer disease and vascular dementia Arch Neurol. May 2004vol. 61 no. 5705 71410.1001/archneur.61.5.705Search in Google Scholar

28Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M. Serum cholesterol changes a*er midlife and late-life cognition: twenty-one-year follow-up study. Neurology, Mar 2007;vol. 68, no. 10:751-756.Solomon A Kareholt I Ngandu T Winblad B Nissinen A Tuomilehto J Soininen H Kivipelto M Serum cholesterol changes a*er midlife and late-life cognition: twenty-one-year follow-up study Neurology, Mar 2007vol. 68 no. 10751 75610.1212/01.wnl.0000256368.57375.b7Search in Google Scholar

29Sparks DL, HunsakerJC3rd, Scheff SW, Kryscio RJ, Henson JL, Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer’s disease. Neurobiol Aging, 1990;vol. 11, no. 6:601-607.Sparks DL Hunsaker JC 3rd Scheff SW Kryscio RJ Henson JL Markesbery WR. Cortical senile plaques in coronary artery disease, aging and Alzheimer’s disease Neurobiol Aging 1990vol. 11 no. 6601 60710.1016/0197-4580(90)90024-TSearch in Google Scholar

30Elias MF, Elias PK, Sullivan LM, Wolf PA, D’Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord. Feb 2003;vol. 27, no. 2:260-268.Elias MF Elias PK Sullivan LM Wolf PA D’Agostino RB. Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study Int J Obes Relat Metab Disord. Feb 2003vol. 27 no. 2260 26810.1038/sj.ijo.80222512587008Search in Google Scholar

31Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. Oct 2001;vol. 154, no. 7:635-641.Luchsinger JA Tang MX Stern Y Shea S Mayeux R Diabetes mellitus and risk of Alzheimer’s disease and dementia with stroke in a multiethnic cohort Am J Epidemiol. Oct 2001vol. 154 no. 7635 64110.1093/aje/154.7.63511581097Search in Google Scholar

32Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center. Neurology, Feb 2005;vol. 64, no. 3:494-500.Honig LS Kukull W Mayeux R Atherosclerosis and AD: analysis of data from the US National Alzheimer’s Coordinating Center Neurology, Feb 2005vol. 64 no. 3494 50010.1212/01.WNL.0000150886.50187.3015699381Search in Google Scholar

33Murdoch JC, Rodger JC, Rao SS, Fletcher CD, Dunnigan MG. Down’s syndrome: an atheroma-free model? Br Med J. Jul 1977;vol. 2, no. 6081:226-228.Murdoch JC Rodger JC Rao SS Fletcher CD Dunnigan MG Down’s syndrome: an atheroma-free model? Br Med J Jul 1977vol. 2 no. 6081226 22810.1136/bmj.2.6081.226Search in Google Scholar

34Brattstrom L, Englund E, Brun A. Does Down syndrome support homocysteine theory of arteriosclerosis? Lancet (London, England), Feb 1987;vol. 1, no. 8529. ENGLAND:391-392.Brattstrom L Englund E Brun A Does Down syndrome support homocysteine theory of arteriosclerosis? Lancet (London, England), Feb 1987vol. 1 no. 8529 ENGLAND:391-39210.1016/S0140-6736(87)91772-7Search in Google Scholar

35Hill DA, Gridley G, Cnattingius S, Mellemkjaer L, Linet M, Adami H-O, Olsen JH, Nyren O, Fraumeni JFJ. “Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med. Mar 2003;vol. 163, no. 6:705-711.Hill DA Gridley G Cnattingius S Mellemkjaer L Linet M Adami H-O Olsen JH Nyren O Fraumeni JFJ. “Mortality and cancer incidence among individuals with Down syndrome. Arch Intern Med Mar 2003vol. 163 no. 6705 71110.1001/archinte.163.6.705Search in Google Scholar

36Day SM, Strauss DJ, Shavelle RM, Reynolds RJ. Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol. Mar 2005;vol. 47, no. 3:171-176.Day SM Strauss DJ Shavelle RM Reynolds RJ Mortality and causes of death in persons with Down syndrome in California Dev Med Child Neurol. Mar 2005vol. 47 no. 3171 17610.1017/S0012162205000319Search in Google Scholar

37Dorner K, Gaethke AS, Tolksdorf M, Schumann KP, Gustmann H. Cholesterol fractions and triglycerides in children and adults with Down’s syndrome. Clin Chim Acta. Oct 1984;vol. 142, no. 3:307-311.Dorner K Gaethke AS Tolksdorf M Schumann KP Gustmann H Cholesterol fractions and triglycerides in children and adults with Down’s syndrome Clin Chim Acta. Oct 1984vol. 142 no. 3307 31110.1016/0009-8981(84)90267-5Search in Google Scholar

38Salo MK, Solakivi-Jaakkola T, Kivimaki T, Nikkari T. Plasma lipids and lipoproteins in Down’s syndrome. Scand J Clin Lab Invest. Sep 1979;vol. 39, no. 5:485-490.Salo MK Solakivi-Jaakkola T Kivimaki T Nikkari T Plasma lipids and lipoproteins in Down’s syndrome Scand J Clin Lab Invest. Sep 1979vol. 39 no. 5485 49010.3109/00365517909106135Search in Google Scholar

39Zamorano A, Guzman M, Aspillaga M, Avendano A, Gatica M. Concentrations of serum lipids in children with Down’s syndrome. Arch Biol Med Exp. (Santiago). 1991;vol. 24, no. 1:49-55.Zamorano A Guzman M Aspillaga M Avendano A Gatica M Concentrations of serum lipids in children with Down’s syndrome Arch Biol Med Exp. (Santiago) 1991vol. 24 no. 149 55Search in Google Scholar

40Adelekan T, Magge S, Shults J, Stallings V, Stettler N. Lipid profiles of children with Down syndrome compared with their siblings. Pediatrics, Jun 2012;vol. 129, no. 6:e1382-1387.Adelekan T Magge S Shults J Stallings V Stettler N Lipid profiles of children with Down syndrome compared with their siblings Pediatrics, Jun 2012vol. 129 no. 6e1382 138710.1542/peds.2011-1262Search in Google Scholar

41Bocconi L, Nava S, Fogliani R, Nicolini U. Trisomy 21 is associated with hypercholesterolemia during intrauterine life. Am J Obstet Gynecol., Mar 1997;vol. 176, no. 3:540-543.Bocconi L Nava S Fogliani R Nicolini U Trisomy 21 is associated with hypercholesterolemia during intrauterine life Am J Obstet Gynecol., Mar 1997vol. 176 no. 3540 54310.1016/S0002-9378(97)70544-1Search in Google Scholar